NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AUPH

Aurinia Pharmaceuticals Inc

Jun 30 • 04:00PM ET

8.47

Dollar change -0.17
Percentage change -1.97	%

Healthcare • Biotechnology • Canada • NASD

Peers: AMGN REGN VRTX ABBV GILD BIIB BMRN INCY SAGE NBIX

| Held by: IWM IWO IBB VTWO VHT AVSC JSML VFMO FESM GWX

Scroll to Statements

Index	RUT	P/E	30.67	EPS (ttm)	0.28	Insider Own	11.64%	Shs Outstand	137.75M	Perf Week	8.17%
Market Cap	1.14B	Forward P/E	11.17	EPS next Y	0.76	Insider Trans	5.74%	Shs Float	119.37M	Perf Month	6.01%
Enterprise Value	909.34M	PEG	-	EPS next Q	0.14	Inst Own	45.06%	Short Float	8.82%	Perf Quarter	2.17%
Income	39.85M	P/S	4.63	EPS this Y	1365.00%	Inst Trans	6.49%	Short Ratio	7.97	Perf Half Y	-5.68%
Sales	247.30M	P/B	3.33	EPS next Y	29.35%	ROA	7.80%	Short Interest	10.53M	Perf YTD	-5.68%
Book/sh	2.54	P/C	3.66	EPS next 5Y	-	ROE	11.23%	52W High	10.67 -20.62%	Perf Year	53.72%
Cash/sh	2.32	P/FCF	18.14	EPS past 3/5Y	- -	ROIC	9.66%	52W Low	5.20 63.04%	Perf 3Y	-26.60%
Dividend Est.	-	EV/EBITDA	12.62	Sales past 3/5Y	72.76% 274.78%	Gross Margin	88.24%	Volatility	5.36% 3.11%	Perf 5Y	-47.33%
Dividend TTM	-	EV/Sales	3.68	EPS Y/Y TTM	164.99%	Oper. Margin	21.26%	ATR (14)	0.29	Perf 10Y	144.80%
Dividend Ex-Date	-	Quick Ratio	5.26	Sales Y/Y TTM	29.20%	Profit Margin	16.11%	RSI (14)	59.90	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	5.93	EPS Q/Q	318.50%	SMA20	4.30%	Beta	1.17	Target Price	10.00
Payout	0.00%	Debt/Eq	0.22	Sales Q/Q	24.18%	SMA50	4.67%	Rel Volume	1.54	Prev Close	8.64
Employees	130	LT Debt/Eq	0.18	Earnings	May 12 BMO	SMA200	5.60%	Avg Volume	1.32M	Price	8.47
IPO	Oct 20, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	60.00% 2.21%	Trades		Volume	2,030,223	Change	-1.97%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight	$34 → $25
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform	$33 → $31
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform	$32
Jan-25-21	Reiterated	H.C. Wainwright	Buy	$30 → $35
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$34 → $28
Jun-17-20	Initiated	BTIG Research	Buy	$20
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy	$27
Dec-16-19	Reiterated	H.C. Wainwright	Buy	$25 → $32
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight	$14 → $16
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$9
Oct-30-17	Reiterated	H.C. Wainwright	Buy	$10 → $12
May-18-17	Reiterated	H.C. Wainwright	Buy	$12 → $10
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight	$14
Mar-22-17	Reiterated	FBR & Co.	Outperform	$9 → $11
Dec-30-16	Reiterated	H.C. Wainwright	Buy	$10 → $8
Aug-17-16	Reiterated	H.C. Wainwright	Buy	$7 → $10
Jun-30-16	Initiated	H.C. Wainwright	Buy	$7
May-08-15	Initiated	MLV & Co	Buy	$9

Show Previous Ratings

Today 06:00AM	Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) (Business Wire)
Jun-29-25 05:00PM	Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 (Business Wire)
Jun-27-25 08:56AM	Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
May-30-25 08:46AM	Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
May-22-25 06:00AM	New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis (Business Wire)
09:24AM	Loading…
May-13-25 09:24AM	Company News for May 13, 2025 (Zacks)
03:03AM	Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-12-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
06:07AM	Aurinia: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 (Business Wire)
May-05-25 06:00AM	Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 (Business Wire)
Apr-30-25 06:00AM	Glass Lewis Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-29-25 06:00AM	ISS Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-26-25 10:54AM	Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (Seeking Alpha)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
04:05PM	Loading…
Apr-23-25 04:05PM	Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting (Business Wire)
09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
Mar-25-25 10:41AM	Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-07-25 04:47PM	Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-04-25 01:14PM	Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
Feb-28-25 02:13AM	Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +5.30%
Feb-27-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates (Zacks) -5.03%
06:28AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress (Business Wire)
Feb-25-25 12:31PM	Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
Feb-20-25 04:05PM	Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 (Business Wire)
Jan-22-25 12:00PM	Aurinia (AUPH) Upgraded to Buy: Here's Why (Zacks)
Dec-10-24 08:30AM	Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options (Zacks) +14.35%
Nov-18-24 05:53PM	Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis (Business Wire)
06:00AM	Loading…
Nov-15-24 06:00AM	Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024 (Business Wire)
Nov-14-24 06:00AM	Aurinia to Participate in Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 10:30AM	Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets (Pharmaceutical Technology)
06:37AM	Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring (TipRanks)
02:12AM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-07-24 07:40AM	Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates (Zacks) +10.90%
06:41AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:10AM	Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth (Business Wire)
06:00AM	Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development (Business Wire)
Oct-30-24 04:05PM	Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 (Business Wire)
06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-11-24 06:00AM	Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 (Business Wire)
Sep-24-24 08:10AM	Aurinia Announces Japan Approval of LUPKYNIS (Voclosporin) to Treat Lupus Nephritis (Business Wire)
Sep-13-24 06:00AM	Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference (Business Wire) +6.84%
Sep-12-24 07:02PM	Significant Acquisition by TANG CAPITAL MANAGEMENT LLC in Aurinia Pharmaceuticals Inc (GuruFocus.com)
04:05PM	Aurinia Announces Board Restructuring (Business Wire)
Sep-06-24 06:32AM	Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases (Clinical Trials Arena) +5.07%
Sep-05-24 06:00AM	Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial (Business Wire)
Aug-28-24 06:00AM	Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-22-24 10:09AM	Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't? (Zacks)
Aug-13-24 08:00AM	Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board (Business Wire)
Aug-01-24 07:10AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
06:14AM	Aurinia: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results (Business Wire)
Jul-19-24 06:00AM	Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 (Business Wire)
Jul-12-24 04:39AM	Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-24 03:27PM	ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM (Business Wire) +6.55%
Jul-02-24 06:00AM	Aurinia to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Jun-17-24 04:46AM	Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Jun-14-24 12:16PM	Aurinia Announces 2024 Annual General Meeting Results (Business Wire) +5.61%
Jun-05-24 06:00AM	Aurinia Presents Safety and Efficacy Profile of LUPKYNIS for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 (Business Wire)
Jun-04-24 05:30PM	Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce (Business Wire)
Jun-03-24 06:30PM	Aurinia Provides Update on Proxy Statement (Business Wire)
May-30-24 06:00AM	Aurinia Will Attend 2024 Jefferies Global Healthcare Conference (Business Wire)
May-14-24 06:00AM	Analysis Showing LUPKYNIS is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024 (Business Wire)
May-09-24 06:00AM	Aurinia Presents Data Reinforcing LUPKYNIS Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 (Business Wire)
May-07-24 09:55AM	How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51% (Zacks)
06:00AM	Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-03-24 01:02PM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 10:56AM	AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:10AM	Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:10AM	Aurinia: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results (Business Wire)
May-01-24 06:00AM	Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month (Business Wire)
Apr-30-24 06:00AM	The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program (Business Wire)
Apr-16-24 10:48AM	UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire)
Apr-15-24 06:00AM	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 (Business Wire)
Apr-09-24 06:00AM	Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-29-24 08:30AM	Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program (Business Wire)
Feb-27-24 08:30AM	Aurinia to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-16-24 09:22AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 07:25AM	Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -24.47%
06:49AM	Aurinia Pharmaceuticals Inc (AUPH) Announces Year-End Financial Results and Strategic Initiatives (GuruFocus.com)
06:32AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:19AM	UPDATE 2-Aurinia Pharma fails to sell itself; to stop trials, cut jobs, buy back shares (Reuters)
06:10AM	Aurinia to cut research after sale process fails to find a buyer (BioPharma Dive)
06:07AM	Aurinia to stop R&D on immunotherapies to focus on kidney disease drug (Reuters)
06:00AM	Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value (Business Wire)
Feb-08-24 10:00AM	Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 08:30AM	Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024 (Business Wire)
Jan-18-24 04:30PM	Kane Biotech Announces Special Meeting of Shareholders (GlobeNewswire)
Jan-05-24 06:00AM	Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results (Business Wire)
Dec-28-23 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
Dec-20-23 06:00AM	Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 (Business Wire) -6.11%
Dec-10-23 06:59AM	This Small Pharma Could Be Targeted, But Would Be Fine Alone, Too (TheStreet.com)
Nov-23-23 09:55AM	Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-20-23 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks) +7.44%
Nov-13-23 06:00AM	Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan (Business Wire)
Nov-07-23 10:30AM	Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS (voclosporin) for Patients with Lupus Nephritis at ACR 2023 (Business Wire)

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Keenan Greg	Chief Medical Officer	Mar 07 '25	Sale	8.23	8,305	68,350	153,484	Mar 07 05:25 PM
Greenleaf Peter	Chief Executive Officer	Mar 03 '25	Sale	8.00	195,593	1,564,744	1,953,892	Mar 04 09:02 PM
Greenleaf Peter	Chief Executive Officer	Mar 04 '25	Sale	7.92	164,947	1,306,380	1,788,945	Mar 04 09:02 PM
Keenan Greg	Chief Medical Officer	Mar 03 '25	Sale	8.00	12,239	97,912	161,789	Mar 04 08:59 PM
Miller Joseph M	Chief Financial Officer	Mar 03 '25	Sale	8.00	61,859	494,872	633,515	Mar 04 08:58 PM
Miller Joseph M	Chief Financial Officer	Mar 04 '25	Sale	7.92	56,154	444,740	577,361	Mar 04 08:58 PM
Robertson Stephen P.	EVP, General Counsel	Mar 03 '25	Sale	8.00	64,872	518,976	566,883	Mar 04 08:57 PM
Robertson Stephen P.	EVP, General Counsel	Mar 04 '25	Sale	7.92	57,607	456,247	509,276	Mar 04 08:57 PM
Donley Matthew Maxwell	Chief Operating Officer	Mar 03 '25	Sale	8.00	65,902	527,216	739,456	Mar 04 08:56 PM
Donley Matthew Maxwell	Chief Operating Officer	Mar 04 '25	Sale	7.92	58,991	467,209	680,465	Mar 04 08:56 PM
TANG KEVIN	Director	Mar 04 '25	Buy	7.96	748,038	5,953,304	10,029,500	Mar 04 05:03 PM
TANG KEVIN	Director	Mar 03 '25	Buy	8.01	452,682	3,625,474	9,281,462	Mar 04 05:03 PM
TANG KEVIN	Director	Feb 28 '25	Buy	7.85	399,280	3,134,348	8,828,780	Mar 04 05:03 PM
TANG KEVIN	Director	Dec 09 '24	Buy	9.09	500,000	4,545,000	8,429,500	Dec 09 04:52 PM
TANG KEVIN	Director	Dec 06 '24	Buy	9.01	400,000	3,604,000	7,929,500	Dec 09 04:52 PM
TANG KEVIN	Director	Dec 05 '24	Buy	8.91	300,000	2,673,000	7,529,500	Dec 09 04:52 PM
Bailey Jeffrey Allen	Director	Nov 11 '24	Sale	8.43	4,557	38,416	13,356	Nov 12 07:29 PM
Smith Karen L.	Director	Nov 11 '24	Sale	8.43	5,241	44,182	12,672	Nov 12 07:20 PM
Habig Scott Michael	Chief Commercial Officer	Aug 06 '24	Sale	5.31	18,249	96,902	456,338	Aug 08 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AUPH

Aurinia Pharmaceuticals Inc

Upgrade your FINVIZ experience